Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China

Nino Balanchivadze; Nicholas J Robert

doi:10.21037/tbcr-23-45

Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR⁺HER2^- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China

Transl Breast Cancer Res. 2023 Oct 23:4:32. doi: 10.21037/tbcr-23-45. eCollection 2023.

Authors

Nino Balanchivadze¹, Nicholas J Robert²

Affiliations

¹ Virginia Oncology Associates/US Oncology Network, Norfolk, VA, USA.
² Ontada, Boston, MA, USA.

No abstract available

Keywords: Hormone receptor-positive human epidermal growth factor receptor-2-negative metastatic breast cancer (HR+HER2− MBC); abemaciclib; personalized medicine; tucidinostat.

Publication types

Editorial